Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Background Peptide vaccines designed to stimulate melanoma-reactive CD4+ T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund’s adjuvant (IFA) would be safe and woul...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kelly T Smith, Nikole Varhegyi, Nolan A Wages, Emily H Hall, Kathleen Haden, Craig L Slingluff, Jr., Lynn T Dengel, Anna Dickinson, Caroline Reed, Elizabeth M Gaughan, Varinder Kaur, Nadejda V Galeassi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2021-01-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/9/1/e000934.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!